Cold Chain Logistics Market for Vaccines to Reach $4.32 Billion by 2030 | Cryoport, DHL Express, United Parcel Service Among Key Players

The global cold chain logistics market for vaccines, valued at USD 4.13 billion in 2025, will reach USD 4.18 billion in 2026 and grow to USD 4.32 billion by 2030, advancing at a CAGR of 0.85% through the forecast period. With over 95% of approved biologics and 90% of all vaccines requiring strict temperature control throughout the supply chain, the stakes for cold chain infrastructure have never been higher. Roots Analysis has published a comprehensive market research report covering industry trends, competitive dynamics, and forecasts through 2030.

To explore the complete findings, request a free sample of the report at https://www.rootsanalysis.com/reports/cold-chain-logistics-for-vaccines/request-sample.html

MARKET OVERVIEW
The cold chain logistics market for vaccines sits at the intersection of global public health, pharmaceutical supply chain management, and logistics technology. Cold chain logistics, in this context, refers to the end-to-end temperature-controlled supply network, encompassing storage, packaging, and transportation, that keeps vaccines and biologics viable from manufacturer to patient. When that chain breaks, the consequences are measurable: WHO data shows that 25% of vaccines are damaged due to cold chain malfunctions, and in some countries, up to 80% of drugs lose potency due to inadequate temperature control during transit.

These numbers underscore the urgency. The post-COVID era brought the cold chain's structural weaknesses into sharp focus when Pfizer's mRNA-based COVID-19 vaccine required storage at -70°C or below, a standard that most emerging markets and equatorial regions simply cannot meet without significant investment in new infrastructure. The challenge extends beyond COVID vaccines. Blood plasma, aerosols, and certain diagnostic kits all require similar handling. As global vaccination programs expand to cover larger populations and new pathogens, the pressure on cold chain providers is increasing at every tier of the supply chain.

Governments and private players are responding. India's government, as recently highlighted in February 2026 by Rinac Systems, is offering subsidy schemes that reimburse 35% of cold chain project costs in general regions and up to 50% in hilly or Northeastern areas. These programs are targeting integrated infrastructure including cold stores, pre-cooling units, and refrigerated transport to cut agrifood and pharma losses nationwide. At the same time, Cold Chain Technologies completed the acquisition of GCCS in March 2025, a move that extended its passive cold chain packaging footprint into Australia and India, growing its Asia-Pacific manufacturing base and life sciences capabilities.

KEY GROWTH DRIVERS
Rising Global Vaccine Demand and Immunization Coverage Goals Global vaccination coverage currently stands at approximately 85%, according to the WHO, but closing the remaining gap requires cold chain infrastructure capable of reaching remote and underserved populations. As governments expand immunization mandates covering more than 15 types of mandatory and optional vaccines, demand for reliable cold chain services will grow proportionally, particularly for the clinical and commercial segments that feed national vaccination programs.

Ultra-Low Temperature Requirements for Next-Generation Vaccines mRNA vaccines and newer biologics are reshaping the logistics requirement baseline. Pfizer's COVID-19 vaccine at -70°C is the clearest example, but a growing portfolio of experimental and approved biologics requires deep frozen or cryogenic storage, a segment where only 13% of logistics providers currently have certified capabilities. This gap is creating significant investment opportunity in specialized cold chain infrastructure.

Consolidation and Strategic Acquisitions Among Service Providers The market has seen meaningful consolidation, with major logistics companies acquiring regional specialists to fill geographic and capability gaps. The March 2025 acquisition of GCCS by Cold Chain Technologies is a recent example. Larger players are building vertically integrated service platforms that combine storage, packaging, and multi-modal transportation, which makes it harder for smaller providers to compete on breadth alone.

Government-Backed Infrastructure Investment Programs Beyond India, multiple governments are channeling public capital into cold chain modernization. Subsidy programs that cover up to 50% of project costs in specific geographies are directly reducing the capital risk for private investors and logistics operators. These programs are accelerating the build-out of cold chain capacity in markets that previously lacked it, which in turn expands the addressable market for commercial vaccine logistics providers.

Connected Cold Chain Solutions Replacing Conventional Methods Automation, IoT-based temperature monitoring, blockchain-enabled traceability, and cloud-integrated supply chain platforms are displacing manual cold chain management. These connected solutions eliminate human handling errors, reduce product loss, and generate the compliance documentation that regulators and pharma companies increasingly require. Providers that have invested in these capabilities are capturing a growing share of high-value contracts.

MARKET SEGMENTATION
The cold chain logistics market for vaccines segments across several dimensions: type of vaccine (COVID-19 and other vaccines), type of service (storage, packaging, and transportation), mode of transportation (ground, air, and ocean), holding temperature (refrigerated, frozen, and deep frozen/cryogenic), scale of operation (clinical and commercial), type of container (active and passive), packaging method (dry ice, liquid nitrogen, and gel packs), and end-user (industry and non-industry). Geographically, the market covers North America, Europe, Asia, Latin America, the Middle East and North Africa, and the Rest of the World.

The commercial-scale segment leads the market, given the volume of routine immunization programs already operating globally. However, the cryogenic/deep frozen sub-segment is the fastest-growing category, fueled by the surge in mRNA vaccine development and cell and gene therapy products that require ultra-low temperature handling. Active container systems are also gaining ground over passive ones, as they offer better temperature assurance over long-haul and multi-modal routes.

To request quote of this report, please visit:
https://www.rootsanalysis.com/reports/cold-chain-logistics-for-vaccines/request-quote.html

REGIONAL INSIGHTS
North America holds the dominant position in the global cold chain logistics market for vaccines, supported by well-established pharmaceutical manufacturing, a dense network of temperature-controlled warehousing, and strong regulatory frameworks issued by bodies including the USFDA and the United States Pharmacopeia. The region's advanced air cargo infrastructure also supports rapid distribution of time-sensitive biologics across domestic and international routes.

Europe represents the second major market, with robust regulatory oversight from the European Medicines Agency setting high standards for cold chain compliance across member states. This regulatory rigor is driving continued investment in qualified facilities and validated shipping systems throughout the region.

Asia is the fastest-growing region in the cold chain logistics market for vaccines. India's government subsidy program is among the most visible policy drivers, but the broader Asia-Pacific build-out reflects rising vaccine production capacity, growing domestic immunization programs, and the entry of international logistics companies like Cold Chain Technologies, which expanded into Australia and India through its 2025 acquisition. The region's large, geographically dispersed populations present both the greatest logistical challenge and the greatest commercial opportunity.

COMPETITIVE LANDSCAPE
Key companies profiled in the Roots Analysis cold chain logistics market report include Cryoport, DHL Express, GAC, Lynden International Logistics, PAREXEL, United Parcel Service, and Yusen Logistics. The full report covers over 75 companies currently active in the market.

The competitive environment is consolidating around a smaller group of providers with broad geographic reach, multi-modal transport capabilities, and validated cold chain systems across refrigerated, frozen, and cryogenic temperature ranges. The primary competitive differentiators are holding temperature range, geographic footprint, and the ability to handle cryogenic transport, a capability that only 13% of tracked providers currently possess. Startups and regional specialists are finding space in last-mile delivery and connected monitoring technology, but large-scale contract wins continue to favor established operators with certified infrastructure and regulatory track records.

Browse Full Report Description + Research Methodology + Table of Content + Infographics here:
https://www.rootsanalysis.com/reports/cold-chain-logistics-for-vaccines.html

Contact Details
Gaurav Chaudhary
Email: Gaurav.chaudhary@rootsanalysis.com or sales@rootsanalysis.com
Website: https://www.rootsanalysis.com

About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we provide bespoke research / consulting services dedicated to serve our clients in the best possible way.

This release was published on openPR.